MVIR:STO
Medivir AB
SEK 1.12
arrow_downward
-1.23%(-0.014) 1D
Nov 17, 5:29:48 PM GMT+1 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
SEK 1.13
High
SEK 1.14
Low
SEK 1.10
Mkt. cap
701.56M
Avg. vol.
2.00M
Volume
1.18M
52-wk high
SEK 2.88
52-wk low
SEK 0.34
EPS
-SEK 0.27
Shares outstanding
624.18M
No. of employees
7
Open
SEK 1.13
High
SEK 1.14
Low
SEK 1.10
Mkt. cap
701.56M
Avg. vol.
2.00M
Volume
1.18M
52-wk high
SEK 2.88
52-wk low
SEK 0.34
EPS
-SEK 0.27
Shares outstanding
624.18M
No. of employees
7
News stories
From web sources and news partners
TradingView
·
4 hours ago
S&P 500, Dow, Nasdaq Futures Power Ahead On Nvidia Outlook Beat — NVDA, TSLA, ANT In Focus
BigGo Finance
·
6 hours ago
Wall Street Split on 2027 S&P 500 Outlook: Wells Fargo's 8,200 vs. Morgan Stanley's 8,700
ChartMill
·
6 hours ago
S&P 500 After-Hours Gainers for Nov. 17, 2026
Traders Union
·
3 hours ago
S&P 500 rises 10 percent amid challenging backdrop, Nate Geraci notes
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB
CEOChristine Lind
Employees7
Founded1988
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitemedivir.com